CPa9-HNE (nordicCPa9-HNE™, serum calprotectin)
PopularA fragment of S100A9 (calprotectin) released by neutrophil elastase measured in blood, enabling precise assessment of active neutrophil-driven inflammation in systemic and tissue-specific conditions.
Key features and values
- Serum-based assay detecting a specific fragment of calprotectin cleaved by human neutrophil elastase (HNE), indicative of neutrophil activation.
- Reflects active neutrophil-driven inflammation, providing insights into disease activity in conditions such as inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF).
- Validated for use in human blood samples, ensuring reliable and reproducible measurements.
- Non-invasive tool for assessing neutrophil activity, suitable for routine blood sampling.
- Elevated CPa9-HNE levels correlate with increased disease activity, aiding in the differentiation between active and remission states.
- Useful for monitoring therapeutic response, with changes in CPa9-HNE levels reflecting the efficacy of anti-inflammatory treatments.
- Facilitates research and development of targeted therapies by providing insights into neutrophil-mediated inflammatory mechanisms.
Description
The CPa9-HNE biomarker assay is designed to quantify a specific fragment of calprotectin (S100A9) generated by the proteolytic activity of human neutrophil elastase (HNE) in serum samples. Calprotectin is a protein complex released by neutrophils during inflammation, and its cleavage by HNE produces the CPa9-HNE neo-epitope, which serves as a specific indicator of active neutrophil-driven inflammation.
This assay has been validated for use in human blood samples, demonstrating its reliability and reproducibility in various clinical and research settings. Elevated serum CPa9-HNE levels have been associated with increased disease activity in conditions such as IBD, COPD, and IPF. The non-invasive nature of the test makes it suitable for routine monitoring of neutrophil activity and the effectiveness of anti-inflammatory therapies.
In addition to its clinical applications, the CPa9-HNE assay serves as a valuable tool in research, facilitating the study of neutrophil-mediated inflammatory mechanisms and the development of targeted treatments aimed at modulating neutrophil activity.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
